Assenagon Asset Management S.A. Trims Position in Solventum Corporation $SOLV

Key Points

• Assenagon Asset Management cut its Solventum stake by 99.2% in the second quarter, selling 359,522 shares and retaining 2,882 shares valued at approximately $222,000.
• Solventum reported stronger-than-expected quarterly results, with EPS of $2.55 versus the $1.91 consensus and revenue of $2.21 billion, up 2.2% year over year. The company maintained fiscal 2026 EPS guidance of $7.10–$7.20.
• Shares opened at $88.53, near their 52-week high, while analyst sentiment remained mixed: the stock has a consensus “Hold” rating and an average price target of $91.64, despite recent price-target increases from Wedbush, UBS and BTIG.

Assenagon Asset Management S.A. cut its stake in Solventum Corporation (NYSE:SOLV - Free Report) by 99.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,882 shares of the company's stock after selling 359,522 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Solventum were worth $222,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Independent Franchise Partners LLP boosted its position in Solventum by 19.0% during the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company's stock valued at $1,216,785,000 after acquiring an additional 2,456,451 shares in the last quarter. State Street Corp lifted its stake in shares of Solventum by 2.0% in the 4th quarter. State Street Corp now owns 6,344,761 shares of the company's stock valued at $502,759,000 after purchasing an additional 124,490 shares during the period. Davis Selected Advisers boosted its position in shares of Solventum by 12.7% during the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company's stock valued at $492,880,000 after purchasing an additional 702,461 shares in the last quarter. Boston Partners boosted its position in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company's stock valued at $338,006,000 after purchasing an additional 959,543 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Solventum by 20.0% in the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company's stock worth $362,375,000 after purchasing an additional 763,308 shares during the period.

Solventum Stock Down 0.1%

NYSE:SOLV opened at $88.53 on Monday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. The firm has a market cap of $15.07 billion, a P/E ratio of 10.82, a P/E/G ratio of 1.14 and a beta of 0.60. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $90.00. The firm has a 50-day simple moving average of $80.11 and a two-hundred day simple moving average of $74.64.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. During the same period last year, the company earned $1.69 EPS. Solventum's revenue for the quarter was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Analysts predict that Solventum Corporation will post 7.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SOLV has been the subject of several recent research reports. Weiss Ratings raised Solventum from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday, July 17th. Wedbush increased their price target on shares of Solventum from $94.00 to $101.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. Wells Fargo & Company lowered their price target on shares of Solventum from $83.00 to $70.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 6th. BTIG Research boosted their price objective on shares of Solventum from $91.00 to $95.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Finally, UBS Group upped their price objective on shares of Solventum from $95.00 to $101.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Seven research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Solventum presently has a consensus rating of "Hold" and an average price target of $91.64.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source